Evidence map›Paper›PMID 27027432›Full record

ArticleOncotarget2016

The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer.

Jean-Philippe Foy, Antonin Tortereau, Carlos Caulin, Vincent Le Texier, Emilie Lavergne, Emilie Thomas, Sylvie Chabaud, David Perol, Joël Lachuer, Wenhua Lang and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Models of Oral Epithelial Dysplasia: A Systematic Review and Temporal Analysis.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026
    Pooled it
  2. Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer.Journal of the National Cancer Institute · 2018
    Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Leukoplakia and Immunology: New Chemoprevention Landscapes?International journal of molecular sciences · 2020
    Review
  14. Molecular cancer research : MCR · 2020
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Biomarkers in Tumorigenesis Using Cancer Cell Lines: A Systematic ReviewAsian Pacific journal of cancer prevention : APJCP · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Jean-Philippe FoyINSERM U1052, Cancer Research Center of Lyon, Lyon, France.
Antonin TortereauUniversité de Lyon, VetAgro Sup, UPSP 2011-03-101, ICE, Marcy-l'Étoile, France.
Carlos CaulinHead and Neck Surgery at The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vincent Le TexierDepartment of Bioinformatics, Centre Léon Bérard, Lyon, France.
Emilie LavergneDepartment of Biostatistics, Centre Léon Bérard, Lyon, France.
Emilie ThomasDepartment of Bioinformatics, Centre Léon Bérard, Lyon, France.
Sylvie ChabaudDepartment of Biostatistics, Centre Léon Bérard, Lyon, France.
David PerolDepartment of Biostatistics, Centre Léon Bérard, Lyon, France.
Joël LachuerINSERM U1052, Cancer Research Center of Lyon, Lyon, France.
Wenhua LangThoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Waun Ki HongDivision of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patrick GoudotDepartment of Oral and Maxillofacial Surgery, University of Pierre Marie Curie-Paris 6, Pitié-Salpêtrière Hospital, Paris, France.
Scott M LippmanUC San Diego Moores Cancer Center, La Jolla, CA, USA.
Chloé BertolusDepartment of Oral and Maxillofacial Surgery, University of Pierre Marie Curie-Paris 6, Pitié-Salpêtrière Hospital, Paris, France.
Pierre SaintignyINSERM U1052, Cancer Research Center of Lyon, Lyon, France.
Centre Léon Bérard · FRThe University of Texas MD Anderson Cancer Center · USCentre de Recherche en Cancérologie de Lyon · FRPitié-Salpêtrière Hospital · FRUniversité Claude Bernard Lyon 1 · FRUniversity of California, San Diego · USVetAgro Sup · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A better understanding of the dynamics of molecular changes occurring during the early stages of oral tumorigenesis may help refine prevention and treatment strategies. We generated genome-wide expression profiles of microdissected normal mucosa, hyperplasia, dysplasia and tumors derived from the 4-NQO mouse model of oral tumorigenesis. Genes differentially expressed between tumor and normal mucosa defined the "tumor gene set" (TGS), including 4 non-overlapping gene subsets that characterize the dynamics of gene expression changes through different stages of disease progression. The majority of gene expression changes occurred early or progressively. The relevance of these mouse gene sets to human disease was tested in multiple datasets including the TCGA and the Genomics of Drug Sensitivity in Cancer project. The TGS was able to discriminate oral squamous cell carcinoma (OSCC) from normal oral mucosa in 3 independent datasets. The OSCC samples enriched in the mouse TGS displayed high frequency of CASP8 mutations, 11q13.3 amplifications and low frequency of PIK3CA mutations. Early changes observed in the 4-NQO model were associated with a trend toward a shorter oral cancer-free survival in patients with oral preneoplasia that was not seen in multivariate analysis. Progressive changes observed in the 4-NQO model were associated with an increased sensitivity to 4 different MEK inhibitors in a panel of 51 squamous cell carcinoma cell lines of the areodigestive tract. In conclusion, the dynamics of molecular changes in the 4-NQO model reveal that MEK inhibition may be relevant to prevention and treatment of a specific molecularly-defined subgroup of OSCC.

Indexed as

Disease Models, Animal4-Nitroquinoline-1-oxideAnimalsAntineoplastic AgentsCarcinogensCarcinoma, Squamous CellCell Line, TumorCell Transformation, NeoplasticGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMice, Inbred CBAMouth MucosaMouth NeoplasmsQuinolones4-Nitroquinoline-1-oxide4-nitroquinolone-1-oxideAntineoplastic AgentsCarcinogensQuinolonesgenome-wide expression profilesoral canceroral preneoplasiapreventiontumorigenesis

Identifiers

PMID27027432
PMCPMC5094973
OpenAlexW2330976739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.